Document is current
Any future updates will be listed below
-
Authors
Horie, Kanta https://orcid.org/0000-0001-7736-2614
Salvadó, Gemma https://orcid.org/0000-0002-5210-9230
Koppisetti, Rama K.
Janelidze, Shorena https://orcid.org/0000-0003-2869-8378
Barthélemy, Nicolas R.
He, Yingxin https://orcid.org/0000-0003-2543-4553
Sato, Chihiro https://orcid.org/0000-0002-7639-8727
Gordon, Brian A. https://orcid.org/0000-0003-2109-2955
Jiang, Hong
Benzinger, Tammie L. S. https://orcid.org/0000-0002-8114-0552
Stomrud, Erik
Holtzman, David M. https://orcid.org/0000-0002-3400-0856
Mattsson-Carlgren, Niklas
Morris, John C.
Palmqvist, Sebastian https://orcid.org/0000-0002-9267-1930
Ossenkoppele, Rik
Schindler, Suzanne E. https://orcid.org/0000-0002-1680-1465
Hansson, Oskar https://orcid.org/0000-0001-8467-7286
Bateman, Randall J. https://orcid.org/0000-0002-7729-1702
-
Funding
Funding for this research was provided by:
The Knight ADRC Developmental Grant
U.S. Department of Health & Human Services | National Institutes of Health (P30 AG066444)
U.S. Department of Health & Human Services | National Institutes of Health (P30 AG066444)
U.S. Department of Health & Human Services | National Institutes of Health (P01 AG03991)
U.S. Department of Health & Human Services | National Institutes of Health (P01 AG026276)
U.S. Department of Health & Human Services | National Institutes of Health (R01AG070941)
Zenith award
- License Information
-
More Information
Article History
Received: 2 July 2024
Accepted: 26 February 2025
First Online: 31 March 2025
Competing interests
: K.H. is an Eisai-sponsored voluntary research associate professor at Washington University and has received a salary from Eisai. Washington University, R.J.B. and D.M.H. have equity ownership interest in C2N Diagnostics. R.J.B. and D.M.H. receive income from C2N Diagnostics for serving on the scientific advisory board. K.H., N.R.B., C.S. and R.J.B. may receive income based on technology (Methods to detect MTBR tau isoforms and use thereof; PCT/US2020/046224) licensed by Washington University to C2N Diagnostics. K.H., H.J., D.M.H. and R.J.B. may receive income based on technology (Anti-tau MTBR antibodies and methods to detect endogenously cleaved fragments of tau and uses thereof; PCT/US2023/072738) licensed by Washington University to C2N Diagnostics. R.J.B. is an unpaid scientific advisory board member of Roche and Biogen, and receives research funding from Avid Radiopharmaceuticals, Janssen, Roche or Genentech, Eli Lilly, Eisai, Biogen, AbbVie, Bristol Myers Squibb and Novartis. O.H. is an employee of Eli Lilly and Lund University and has previously acquired research support (for Lund University) from AVID Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare and Roche. In the past 2 years, he has received consultancy or speaker fees from ALZpath, BioArctic, Biogen, Bristol Meyer Squibb, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. S.E.S. has served on scientific advisory boards or given lectures for Eisai, Eli Lilly and Novo Nordisk. D.M.H. is on the scientific advisory board of Genentech, Denali and Cajal Neurosciences and Switch, and consults for Asteroid and Roche. S.P. has acquired research support (for the institution) from ki elements or ADDF and Avid. In the past 2 years, he has received consultancy or speaker fees from BioArctic, Biogen, Eisai, Lilly, Novo Nordisk and Roche. The other authors declare no competing interests.
